260 related articles for article (PubMed ID: 30362671)
1. Cancer stem cell markers ALDH1 and CD44+/CD24- phenotype and their prognosis impact in invasive ductal carcinoma.
Rabinovich I; Sebastião APM; Lima RS; Urban CA; Junior ES; Anselmi KF; Elifio-Esposito S; De Noronha L; Moreno-Amaral AN
Eur J Histochem; 2018 Sep; 62(3):. PubMed ID: 30362671
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
Ricardo S; Vieira AF; Gerhard R; Leitão D; Pinto R; Cameselle-Teijeiro JF; Milanezi F; Schmitt F; Paredes J
J Clin Pathol; 2011 Nov; 64(11):937-46. PubMed ID: 21680574
[TBL] [Abstract][Full Text] [Related]
3. The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer.
Kapucuoğlu N; Bozkurt KK; Başpınar Ş; Koçer M; Eroğlu HE; Akdeniz R; Akçil M
Pathol Res Pract; 2015 Oct; 211(10):740-7. PubMed ID: 26298632
[TBL] [Abstract][Full Text] [Related]
4. Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types.
de Beça FF; Caetano P; Gerhard R; Alvarenga CA; Gomes M; Paredes J; Schmitt F
J Clin Pathol; 2013 Mar; 66(3):187-91. PubMed ID: 23112116
[TBL] [Abstract][Full Text] [Related]
5. ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype.
Zhong Y; Shen S; Zhou Y; Mao F; Guan J; Lin Y; Xu Y; Sun Q
Med Oncol; 2014 Mar; 31(3):864. PubMed ID: 24519209
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer stem cells and intrinsic subtypes: controversies rage on.
Nakshatri H; Srour EF; Badve S
Curr Stem Cell Res Ther; 2009 Jan; 4(1):50-60. PubMed ID: 19149630
[TBL] [Abstract][Full Text] [Related]
7. Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis.
Li W; Ma H; Zhang J; Zhu L; Wang C; Yang Y
Sci Rep; 2017 Oct; 7(1):13856. PubMed ID: 29062075
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of putative cancer stem cell markers (CD24, CD44, CD133, and ALDH1) in human papillary thyroid carcinoma.
Han SA; Jang JH; Won KY; Lim SJ; Song JY
Pathol Res Pract; 2017 Aug; 213(8):956-963. PubMed ID: 28687160
[TBL] [Abstract][Full Text] [Related]
9. Distinct patterns of promoter CpG island methylation of breast cancer subtypes are associated with stem cell phenotypes.
Park SY; Kwon HJ; Choi Y; Lee HE; Kim SW; Kim JH; Kim IA; Jung N; Cho NY; Kang GH
Mod Pathol; 2012 Feb; 25(2):185-96. PubMed ID: 22037257
[TBL] [Abstract][Full Text] [Related]
10. Are CD44
Ryspayeva DE; Smolanka II; Dudnichenko АS; Lyashenko AA; Grinevich YA; Gurianov VG; Koshubarova MV; Seleznev AA
Exp Oncol; 2017 Sep; 39(3):224-228. PubMed ID: 28967636
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma.
Chen Y; Song J; Jiang Y; Yu C; Ma Z
Int J Clin Exp Pathol; 2015; 8(9):11287-95. PubMed ID: 26617852
[TBL] [Abstract][Full Text] [Related]
12. Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer.
Seo AN; Lee HJ; Kim EJ; Jang MH; Kim YJ; Kim JH; Kim SW; Ryu HS; Park IA; Im SA; Gong G; Jung KH; Kim HJ; Park SY
Br J Cancer; 2016 May; 114(10):1109-16. PubMed ID: 27115469
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological significance of cancer stem cell markers CD44 and ALDH1 expression in breast cancer.
Louhichi T; Ziadi S; Saad H; Dhiab MB; Mestiri S; Trimeche M
Breast Cancer; 2018 Nov; 25(6):698-705. PubMed ID: 29845398
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer.
Park SY; Lee HE; Li H; Shipitsin M; Gelman R; Polyak K
Clin Cancer Res; 2010 Feb; 16(3):876-87. PubMed ID: 20103682
[TBL] [Abstract][Full Text] [Related]
15. Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.
Bane A; Viloria-Petit A; Pinnaduwage D; Mulligan AM; O'Malley FP; Andrulis IL
Breast Cancer Res Treat; 2013 Jul; 140(1):195-205. PubMed ID: 23813303
[TBL] [Abstract][Full Text] [Related]
16. Features of CD44+/CD24-low phenotypic cell distribution in relation to predictive markers and molecular subtypes of invasive ductal carcinoma of the breast.
Gudadze M; Kankava Q; Mariamidze A; Burkadze G
Georgian Med News; 2014 Mar; (228):81-7. PubMed ID: 24743129
[TBL] [Abstract][Full Text] [Related]
17. The role of CD44+/CD24-/low biomarker for screening, diagnosis and monitoring of breast cancer.
Camerlingo R; Ferraro GA; De Francesco F; Romano M; Nicoletti G; Di Bonito M; Rinaldo M; D'Andrea F; Pirozzi G
Oncol Rep; 2014 Mar; 31(3):1127-32. PubMed ID: 24366074
[TBL] [Abstract][Full Text] [Related]
18. Distribution of CD44/CD24 positive cells in ductal invasive carcinoma of breast of different grade and molecular subtype.
Gudadze M; Kankava K; Mariamidze A; Mosidze T; Burkadze G
Georgian Med News; 2013 Sep; (222):50-7. PubMed ID: 24099815
[TBL] [Abstract][Full Text] [Related]
19. The role of ALDH1A1 in contributing to breast tumour aggressiveness: A study conducted in an African population.
Gyan E; Green A; Ahenkorah-Fondjo L; Jackson A; Toss MS; Akakpo PK; Derkyi-Kwarteng L; Rahman GA; Owiredu W
Ann Diagn Pathol; 2021 Apr; 51():151696. PubMed ID: 33460998
[TBL] [Abstract][Full Text] [Related]
20. Cancer stem cell markers are associated with adverse biomarker profiles and molecular subtypes of breast cancer.
Tsang JY; Huang YH; Luo MH; Ni YB; Chan SK; Lui PC; Yu AM; Tan PH; Tse GM
Breast Cancer Res Treat; 2012 Nov; 136(2):407-17. PubMed ID: 23053657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
